BACKGROUND: The purpose of this study was to determine whether the disease-free interval (DFI) between treatment of primary head and neck cutaneous squamous cell carcinoma (SCC) and the development of regional metastases is an independent prognostic factor. METHODS: A retrospective analysis of 229 patients with metastatic nodal head and neck cutaneous SCC, treated with curative intent by surgery ± adjuvant radiotherapy was conducted. RESULTS: After adjusting for the effect of nodal staging, extracapsular spread, involved margins, adjuvant radiotherapy, and immunosuppression, a short DFI (≤9 months vs >9 months) was a significant predictor of disease-related mortality (hazard ratio [HR], 3.0; 95% confidence interval [CI], 1.4-6.5; p = .004) and locoregional relapse (HR, 2.0; 95% CI, 1.1-4.0; p = .044). CONCLUSION: The DFI is a potentially powerful independent prognostic factor in patients with regional metastases secondary to head and neck cutaneous SCC. It provides information before definitive treatment that may ultimately assist clinicians in applying a risk-adapted management paradigm.
BACKGROUND: The purpose of this study was to determine whether the disease-free interval (DFI) between treatment of primary head and neck cutaneous squamous cell carcinoma (SCC) and the development of regional metastases is an independent prognostic factor. METHODS: A retrospective analysis of 229 patients with metastatic nodal head and neck cutaneous SCC, treated with curative intent by surgery ± adjuvant radiotherapy was conducted. RESULTS: After adjusting for the effect of nodal staging, extracapsular spread, involved margins, adjuvant radiotherapy, and immunosuppression, a short DFI (≤9 months vs >9 months) was a significant predictor of disease-related mortality (hazard ratio [HR], 3.0; 95% confidence interval [CI], 1.4-6.5; p = .004) and locoregional relapse (HR, 2.0; 95% CI, 1.1-4.0; p = .044). CONCLUSION: The DFI is a potentially powerful independent prognostic factor in patients with regional metastases secondary to head and neck cutaneous SCC. It provides information before definitive treatment that may ultimately assist clinicians in applying a risk-adapted management paradigm.
Authors: Bram van Leer; Alet J G Leus; Boukje A C van Dijk; Marloes S van Kester; Gyorgy B Halmos; Gilles F H Diercks; Bert van der Vegt; Jeroen Vister; Emoke Rácz; Boudewijn E C Plaat Journal: Front Oncol Date: 2022-05-30 Impact factor: 5.738
Authors: Axel Sahovaler; Rohin J Krishnan; David H Yeh; Qi Zhou; David Palma; Kevin Fung; John Yoo; Anthony Nichols; S Danielle MacNeil Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-04-01 Impact factor: 6.223
Authors: A J G Leus; M Frie; M S Haisma; J B Terra; B E C Plaat; R J H M Steenbakkers; G B Halmos; E Rácz Journal: J Eur Acad Dermatol Venereol Date: 2020-03-30 Impact factor: 6.166
Authors: Joshua Lubov; Mathilde Labbé; Krystelle Sioufi; Grégoire B Morand; Michael P Hier; Manish Khanna; Khalil Sultanem; Alex M Mlynarek Journal: J Otolaryngol Head Neck Surg Date: 2021-09-07
Authors: Mateusz Szewczyk; Jakub Pazdrowski; Paweł Golusiński; Aleksandra Dańczak-Pazdrowska; Mariola Pawlaczyk; Jacek Sygut; Andrzej Marszałek; Wojciech Golusiński Journal: Postepy Dermatol Alergol Date: 2018-08-21 Impact factor: 1.837